Biotech Values

[DewDiligence]

CLLS/Calyxt—I concur, of course. A lot of stuff you read in S-1 filings is utter nonsense, but investment bankers evidently like it that way.

As previously posted, I'm skeptical of Calyxt's claim that consumers will view the kind of gene editing they do as “non-GMO” (regardless of how regulators regulate the products).

Still, if the IPO gets off and the valuation looks reasonable, I might be a buyer. I like ag-biotech as an investment theme, and my only such holding (MON) is in the process of being acquired.